1.
|
13 p, 1.0 MB |
Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation
/
Vella Bonanno, Patricia (Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde) ;
Ermisch, Michael (Pharmaceutical Department, National Association of Statutory Health Insurance Funds) ;
Godman, Brian (Karolinska Institutet (Estocolm, Suècia). Division of Clinical Pharmacology) ;
Martin, Antony P. (Health Economics Centre, University of Liverpool Management School) ;
Van Den Bergh, Jesper (Department of Health) ;
Bezmelnitsyna, Liudmila (National Research Institution for Public Health) ;
Bucsics, Anna (Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)) ;
Arickx, Francis (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ;
Bybau, Alexander (Zilveren Kruis Achmea) ;
Bochenek, Tomasz (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College) ;
van de Casteele, Marc (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Eriksson, Irene (Karolinska Institutet (Estocolm, Suècia). Department of Medicine Solna) ;
Fürst, Jurij (Medicinal Products Department, Health Insurance Institute of Slovenia) ;
Gad, Mohamed (Global Health and Development Group, Imperial College) ;
Greičiūtė-Kuprijanov, Ieva (Department of Pharmacy, Ministry of Health of the Republic of Lithuania) ;
van der Graaff, Martin (National Health Care Institute (ZIN)) ;
Gulbinovič, Jolanta (State Medicines Control Agency) ;
Jones, Jan (Scottish Medicines Consortium) ;
Joppi, Roberta (Clinical Research and Drug Assessment Unit) ;
Kalaba, Marija (Pediatric Cardiology, Primary Healthcare Centre "Zemun") ;
Laius, Ott (Department of Post-authorisation Safety, State Agency of Medicines) ;
Langner, Irene (Wissenschaftliches Institut der AOK) ;
Mardare, Ileana (Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest) ;
Markovic-Pekovic, Vanda (Department of Social Pharmacy, Medical Faculty, University of Banja Luka) ;
Magnusson, Einar (Department of Health Services, Ministry of Health) ;
Melien, Oyvind (Norwegian Directorate for Health) ;
Meshkov, Dmitry O. (Department of Health) ;
Petrova, Guenka I. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia) ;
Selke, Gisbert (Wissenschaftliches Institut der AOK) ;
Sermet, Catherine (Institut de Recherche et Documentation en Economie de la Santé (IRDES)) ;
Simoens, Steven (KU Leuven Department of Pharmaceutical and Pharmacological Sciences) ;
Schuurman, Ad (National Health Care Institute (ZIN)) ;
Ramos, Ricardo (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ;
Rodrigues, Jorge (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ;
Zara, Corinne (Servei Català de la Salut) ;
Zebedin-Brandl, Eva (Main Association of Austrian Social Insurance Institutions. Department of Pharmaceutical Affairs) ;
Haycox, Alan (Health Economics Centre, University of Liverpool Management School) ;
Universitat Autònoma de Barcelona
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. [...]
2017 - 10.3389/fphar.2017.00497
Frontiers in Pharmacology, Vol. 8 (august 2017)
|
|
2.
|
11 p, 1.1 MB |
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
/
Godman, Brian (University of Strathclyde) ;
Malmström, Rickard E. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ;
Jayathissa, Sisira (Hutt Valley DHB. Department of Medicine) ;
McTaggart, Stuart (NHS National Services Scotland) ;
Cars, Thomas (Uppsala University. Department of Medical Sciences) ;
Alvarez-Madrazo, Samantha (University of Strathclyde) ;
Baumgärtel, Christoph (Austrian Medicines and Medical Devices Agency) ;
Brzezinska, Anna (Agency for Health Technology Assessment) ;
Bucsics, Anna (Hauptverband der Österreichischen Sozialversicherungsträger) ;
Campbell, Stephen (University of Manchester. Centre for Primary Care) ;
Eriksson, Irene (Stockholm County Council. Department of Healthcare Development) ;
Finlayson, Alexander (University of Oxford. Green Templeton College) ;
Fürst, Jurij (Health Insurance Institute) ;
Garuoliene, Kristina (National Health Insurance Fund) ;
Gutiérrez-Ibarluzea, Iñaki (Osasun Saila. Ezagutu Osteba arloa) ;
Hviding, Krystyna (Norwegian Medicines Agency) ;
Herholz, Harald (Kassenärztliche Vereinigung Hessen) ;
Joppi, Roberta (Azienda Sanitaria Locale of Verona. Pharmaceutical Drug Department) ;
Kalaba, Marija (Republic Institute for Health. Department of Medicines and Pharmacoeconomics) ;
Laius, Ott (State Agency of Medicines) ;
Malinowska, Kamila (National Health Fund. Drug Management Department) ;
Pedersen, Hanne B. (Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe) ;
Markovic-Pekovic, Vanda (Ministry of Health and Social Welfare) ;
Piessnegger, Jutta (Hauptverband der Österreichischen Sozialversicherungsträger) ;
Selke, Gisbert (Wissenschaftliches Institut der AOK (WidO)) ;
Sermet, Catherine (IRDES) ;
Spillane, Susan (Trinity College. Department of Pharmacology and Therapeutics) ;
Tomek, Dominik (Slovak Medical University. Faculty of Pharmacy) ;
Vončina, Luka (Ministry of Health) ;
Vlahović-Palčevski, Vera (University Hospital Rijeka. Unit for Clinical Pharmacology) ;
Wale, Janet (Independent Consumer Advocate, VIC) ;
Wladysiuk, Magdalena (HTA Consulting) ;
van Woerkom, Menno (Dutch Institute for Rational Use of Medicine) ;
Zara, Corinne (Institut Català de la Salut) ;
Gustafsson, Lars L. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ;
Universitat Autònoma de Barcelona
Background : There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. [...]
2014 - 10.3389/fphar.2014.00109
Frontiers in Pharmacology, Vol. 5 (june 2014)
|
|